Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
about
Minimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentDeep Response in Multiple Myeloma: A Critical ReviewEuropean perspective on multiple myeloma treatment strategies in 2014New criteria for response assessment: role of minimal residual disease in multiple myelomaTowards Stratified Medicine in Plasma Cell MyelomaPrognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaDifferentiation stage of myeloma plasma cells: biological and clinical significance.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myelomaComplete response after autologous stem cell transplant in multiple myelomaBlood and marrow transplant clinical trials network state of the Science Symposium 2014Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.The Evolution of Prognostic Factors in Multiple Myeloma.Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsMultiple myeloma: disease response assessment.Multiple Myeloma Minimal Residual Disease.Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.Mechanisms of Resistance in Multiple Myeloma.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.Standardisation of minimal residual disease in multiple myeloma.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Assessment of minimal residual disease in myeloma and the need for a consensus approach.Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation methodRegulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients.Current applications of multiparameter flow cytometry in plasma cell disorders.Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.Minimal residual disease in multiple myeloma: Benefits of flow cytometry.High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.Molecular detection of minimal residual disease in multiple myeloma.
P2860
Q26768653-DF4812F8-FAA1-42D0-A6D3-088928734F83Q26771228-3D97A09B-237B-4B66-86A1-A1683DA494CEQ27005966-C52D1DB0-D8B6-453C-857D-8430038FE0E1Q27027512-5A8014CC-53B6-43AB-BABB-C9B593B70CC5Q28074994-1BC213F8-2D48-422B-911F-B50161174ECDQ33621587-913DE053-0C5F-4618-AEF7-46E9C144E767Q33712516-B44647F1-6E12-4F7B-8451-9B621EDA60FAQ34380489-B6F185AF-CCDB-4CFB-9686-E27233C5B55EQ34454581-9E6825B0-06C5-48A3-8574-D099A94B5088Q35000475-CD468259-DFCC-485A-B7E1-C8402BF77F6AQ35591760-563D50FD-5456-4C5C-8111-FFBCD265FD16Q36592788-01BE8A48-C3D6-4A4F-9EE5-9E09089092B0Q37032148-F9977D3B-8CC6-4CF3-8960-DAF669CD4F6BQ37683483-ED9CEDFB-973D-418B-B6CD-36793C5485C2Q37701511-0713C1E0-5CCB-45D7-8F72-E44DF074A243Q38534837-BE39FD17-9CB3-4F05-9713-B25E9E4A986BQ38543122-E2D25ECE-B049-45EC-A0C7-DC0E2F2CB5D6Q38789282-D1FBF7A5-6758-4F29-88AA-46FCA09433A3Q38895092-27C8739A-B985-4A05-9964-64AD09F03DC5Q38970590-CFA646DA-5E09-426A-9C0B-D3C374BFF062Q39050210-970A4F58-4982-45D5-B423-70F3A64677F2Q39185604-5B995985-E3BB-45EC-96A2-1D35913A8423Q39386287-21BC4B52-24FB-41B2-A3D1-ED0464305826Q39410899-65BDFD64-6DAB-433A-A5F0-D300FD444839Q40469944-34F625EA-DA44-40E2-B97F-E7DEDAC10F04Q41556524-B6986E16-4D34-4DE8-95DB-279BCBCB8E04Q41557109-5D7748CE-326F-419A-B236-E7ABA7501CBFQ41644146-36EAFD74-B46D-4AEC-85AE-91490654D0C0Q42050819-16115584-20F9-4A07-AFCE-D1A6EF53E2E1Q42385408-7F1CDD4C-302C-48E0-9042-BCBE58F6EA77Q43837244-EA36DDD0-9ED7-46DA-85A3-9B08A3419E01Q46215222-7D721E8B-5855-4070-BFA0-5D4274819981Q47110039-DF650451-F7E9-49C1-8CE5-6F42CA28B6C4Q47164979-0A8D48FA-6753-48F8-B9EA-7140CE07DE48Q47281717-82268B6C-BCC5-44DF-99BF-233CF0FFAFE5Q47307819-930BE926-E570-45D9-A062-7AD8EC076D68Q47672299-F0573A1B-41E7-4E84-B55A-DFA90A462D83Q47744241-056CF300-51F5-49F1-8209-04362FFCC89EQ48268599-C1608572-9140-47C4-9F5D-AB3680D93EB4Q48371783-7CCB04D9-F014-4DF7-A556-163B7B6C815C
P2860
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Critical evaluation of ASO RQ- ...... analysis with flow cytometry.
@en
Critical evaluation of ASO RQ- ...... analysis with flow cytometry.
@nl
type
label
Critical evaluation of ASO RQ- ...... analysis with flow cytometry.
@en
Critical evaluation of ASO RQ- ...... analysis with flow cytometry.
@nl
prefLabel
Critical evaluation of ASO RQ- ...... analysis with flow cytometry.
@en
Critical evaluation of ASO RQ- ...... analysis with flow cytometry.
@nl
P2093
P2860
P50
P356
P1433
P1476
Critical evaluation of ASO RQ- ...... e analysis with flow cytometry
@en
P2093
A Balanzategui
E Sebastián
J F S Miguel
J J Lahuerta
J de la Rubia
P2860
P2888
P304
P356
10.1038/LEU.2013.217
P50
P577
2013-07-17T00:00:00Z